BACKGROUND: Clear cell renal cell carcinoma (CCRCC) is the most predominant renal tumour with unpredictable tumour behaviour. The aim of the study is to investigate the prognostic value of vascular endothelial growth factor A (VEGF-A) expression in CCRCC and to correlate it with other histological parameters as well as with patient's survival.
Introduction
Renal cell carcinomas (RCCs) are the seventh most common histological type of cancer in the Western world and have maintained an increasing prevalence, representing 1% to 3% of all malignant visceral neoplasms [1] . The mortality incidence ratio is higher in RCC than in other urological malignancies [2] . RCC has been reported to be resistant to radiation or chemotherapy, and the prognosis for these patients remains poor [3] . Histopathological evaluations of RCC have revealed that highly vascularized neoplasm is demonstrating clear evidence of abundant angiogenesis and abnormal blood vessel development [4] . This notion has thus raised considerable concerns regarding the development of agio suppressive therapies for RCC. Until now, many angiogenic molecules have been identified [5] . Vascular endothelial growth factor (VEGF) is a potent endothelial cell mitogen and is an important component of the angiogenic stimulus in a range of human neoplasias [6] . VEGF is a multifunctional cytokine that can increase microvascular permeability [7] and stimulate endothelial cell growth and angiogenesis [8] . Several factors can influence VEGF expression, including hypoxia [9] and transform growth factor-β [10] . Once VEGF binds to VEGF receptors, receptor dimerization and autophosphorylation are induced and downstream signalling via http://www.mjms.mk/ http://www.id-press.eu/mjms/ several secondary messengers, including several protein kinases and phosphatases, are activated. This supports a proangiogenic phenotype [11] .
The aim of the study is to investigate the prognostic value of VEGF-A expression in Clear cell renal cell carcinoma (CCRCC) and to correlate it with other histological parameters as well as with patient's survival rate.
Materials and Methods

Patients
The study included a total of 40 patients with histopathologically verified RCC after surgery in the period between January 2008 and July 2014. Before surgery, all patients signed an informed consent form. This research was approved by the ethics committee at the Medical Faculty -Prishtina University. There were 19 men and 21 women, with a median age of 60.3 years (range 36 -81 years). Among 40 patients, 32 patients undergone nephrectomy, seven partial nephrectomies (NSS), and one bilateral radical nephrectomy due to bilateral RCC. None of the patients had been treated with radiation, chemotherapy, or immunotherapy before surgery. Most of the patients were followed-up using clinical and radiological examinations at regular intervals. Survival was determined from the nephrectomy time to the latest follow-up. At the latest follow-up, 33 patients were alive with a median follow-up time of 26 months, (range 2 -72 months), 6 of them died of RCC with a median survival rate of 9 months (range 2 -24 months), and one patient died of unrelated causes 10 months after nephrectomy.
The control group included tissue sections of normal kidneys from 20 cases provided by forensic autopsies at the Department of Forensic Pathology in Prishtina, Kosovo.
Morphological grading
Histopathological nuclear grading has been performed by pathologists in the Institute of Pathology, University Clinical Center of Kosovo, based on the worse histological features, according to Fuhrman and co-workers [12] . As a result, 25 (62.5 %) cases were classified as Fuhrman grade 2; 13 (32.5 %) cases as Fuhrman grade 3, and 2 (5.0 %) cases as Fuhrman grade 4. Nuclear grade was assessed by combining nuclear grades 1 and 2 into one group, and nuclear grades 3 and 4 as another group.
Tumor staging
The tumour stage has been determined by TNM classification system 2010 [13] . This classification system has been used to evaluate the tumour size, the status of the regional lymph nodes and the perinephric tissue, and tumour invasion through the renal capsule into perirenal fat or major renal veins at the renal hilum. There have been identified 17 cases of stage I (42.5%), 8 cases of stage II (20.0 %), 12 cases of stage III (30.0 %), and 3 cases of stage IV (7.5%). The tumour size has been measured as the maximal diameter of the tumour mass. The median tumour diameter was 71.0 mm (range 13-125 mm).
Tissue collection and preparation
Tumour and kidney cortex tissue samples were obtained from the surgical specimen. Each sample was divided into smaller pieces (1-2 cm^2). Samples were formalin fixed and paraffin embedded for immuno-histochemical staining and morphologic examination.
Immunohistochemestry
Representative paraffin tumour blocks were selected by primary evaluation of haematoxylin/eosinstained slides. For immunohistochemical evaluation 4-μm, thick paraffin blocks were sliced. Slides were treated with standard procedures of deparaffinisation, rehydration, microwave heating and immunohistochemical (IHC) staining. For the IHC techniques, the antibodies VEGF-A (A-20, 1:150 dilution; Santa Cruz Biotechnology Inc, CA, USA) were used.
IHC results were independently evaluated by two specialised pathologists, blinded to each patient's clinical data. VEGF-A protein expression mainly was observed in the cytoplasm of the tumour cells. IHC VEGF-An expression was quantified by estimating the volume density and staining intensity on a three-grade scale. A semiquantitative scoring system was used, based on staining intensity (0, negative; 1, weak; 2, intermediate; 3, strong), which was corresponded to the percentage of positive stained cells (0, 0%; 1, < 25% positive; 2, 26-50% positive; 3, ≥ 50% positive) [14] .
The positive and uniform IHC VEGF-A expressions in normal kidney tubular cells were used as a control for immuno-histochemical evaluation of positive IHC VEGF-An expression in tumour cells.
Microvessel counting was used for angiogenesis assessment. Immunostained tumour sections were scanned at high power magnification (200 x) to identify the areas with highest vascular density so-called "hot -spots". Determining microvessel density was expressed as the number of stained microvessels per optical field. Any cell or cell cluster showing positive CD31 staining was counted as a vessel, as described in the Weidner method [15] .
The degree of necrosis and degree of haemorrhage has been assessed with the presence versus absence of haemorrhage and necrosis.
Statistical methods
The Mann-Whitney U test was used to identify differences in not-parametric variables for two independent groups, and the Kruskal-Wallis test was used for comparison of more than two groups. Spearman rank correlation test was used to compare the relationship between sets of non-parametric variables that did not demonstrate a linear relation. Chi-Square test was used to evaluate differences in proportions of observations between independent groups. Fisher's exact test was used when the sample size was too small to use the chi-square test. The median value was chosen as the cut-off value. Survival data was analysed using the Kaplan-Meier method, and comparison of survival times for groups was performed with the log-rank test. The variables were dichotomously tested and analysed as continuous in a univariate Cox regression analysis. Survival time was measured from the date of nephrectomy to the date of death or latest follow-up. In all tests, a two-tailed significance level was set to < 0.05.
Results
Immunohistochemical assessment of VEGF-A expression
In normal renal tissues, VEGF-A expression was limited to the cytoplasm of tubular epithelium, smooth muscle cells and macrophages in the interstitial tissue, and mesangial cells in the glomerule (Fig. 1) . In CCRCC, VEGF-A was expressed in the cytoplasm of tumour cells, endothelial cells, and stromal fibroblasts (Fig. 2) . The average value of VEGF-A expression in patients with CCRCC nuclear grade 2 was 2.80 (DS ± 0.41), while in patients with CCRCC nuclear grade 3 and 4 was 2.67 (DS ± 0.49). The statistical analysis showed no difference between VEGF-A values and the tumour nuclear grade (U' = 212.5, P = 0.484). The average value of VEGF-A expression in patients with CCRCC pathological stage I and II was 2.88 (DS ± 0.33), while in patients with CCRCC pathological stage III and IV was 2.53 (DS ± 0.52). Additionally no difference between VEGF-A values regarding the tumor stage was recorded (U' = 252.5, P = 0.067). http://www.mjms.mk/ http://www.id-press.eu/mjms/
Correlations between VEGF A and other clinicopathologic parameters
VEGF A expression values in CCRCC was positively correlated with Disease free survival (DFS) (r = 0.335, P = 0.034) and the tumor necrosis degree (r = 0.181, P = 0.262). VEGF A expression values in CCRCC was not correlated with CD 31 expression (r= -0.09, P = 0.549) and Progression free survival (PFS) (r = -0.07, P=0.838). 
Discussion
Angiogenesis is controlled by angiogenic factors that regulate extracellular matrix remodelling, endothelial cell proliferation, capillary differentiation, and anastomosis necessary to establish a blood supply. Angiogenic stimuli are released by tumour cells, stromal cells, and inflammatory cells recruited to the tumour site [16] . Among several identified peptides with angiogenic properties, the vascular endothelial growth factor (VEGF) is thought to play a major role in tumour angiogenesis [17] . Tumour angiogenesis has been well documented both in experimental and clinical studies, and the degree of angiogenesis was closely associated with tumour progression and shorter patient survival in many types of cancers [18] , whereas data for RCC are controversial [19] .
The results showed that the VEGF-A expression in patients with CCRCC was higher than in normal kidney tissues. Despite other studies in which the control group consisted of non-tumorous tissue from the surrounding of the tumour, the control group of our study included normal kidney tissues provided by the forensic autopsies. Given that VEGF-A expression was higher in CCRCC, it could be postulated that VEGF-A expression might have an effect on the non-tumorous tissue of the same kidney making such control group unreliable for comparison. On the other hand, the control tissues of this study did not show pathological changes and therefore can be deemed more credible.
In the current research, VEGF-A expression in CCRCC was positively correlated with the tumor necrosis degree (r = 0.181, P = 0.262). In RiouxLeclercq N [20] study, VEGF expression was also correlated with tumour necrosis (P = 0.001). Based on IHC data, several investigators have reported that VEGF overexpression in CCRCC was associated with tumour stage, pathological grade, histological vein invasion and prognosis [21, 22] . Tumour angiogenesis was reported to be the only significant predictor of prognosis in low stage RCC [23] . However, angiogenesis was not related to the tumour malignancy or patient survival of RCC [24] . Verheul et al. reported that VEGF expression using IHC in CCRCC was not significantly correlated with prognosis [25] .
An important finding of our study was that VEGF-A expression is significantly correlated with prognosis. This discrepancy in IHC results could be due to several factors including differences in fixation, scoring and staining methods [25] [26] [27] .
Compared to other studies, our approach was to comprehend different factors such as the tumour grade and stage with macroscopic features such as tumour size, haemorrhage degree and tumour necrosis degree. Our study showed a decrease in VEGF-A expression in more advanced tumour grade and stage and large tumour sizes. Although not statistically significant, the study results showed that higher VEGF expression is a good prognostic factor for low pathologic tumour stage CCRCCs, similarly to that described in the study of Nativ et al. [23] .
Our study showed a positive correlation between VEGF-A expression tumour necrosis degree and a negative correlation between VEGF-A expression and tumour haemorrhage degree. Minardi et al. in his study could not find a correlation between the endothelial and tumoral cells cytoplasmic expression of VEGF and tumour necrosis [26] .
Also, a correlation between VEGF-A expression and Microvessel density (MVD) measured through CD31 was not recorded. Even though, Djordjevica et al. reported an inverse correlation between VEGF expression and MVD, which can be found in CCRCC [27] .
In our study, lower VEGF-A expression was also associated with an increased risk of renal cancer death and recurrence in CCRCC patients. Surgical removal of CCRCC with high VEGF-A expression in the lower stages, without metastasis, is associated with increased cancer-free survival. These circumstances explain VEGF-A expression is closely linked with better survival.
The trend of decreasing levels of VEGF expression in advanced tumour stages may indicate that angiogenic activity is an early event in tumour growth, but during later tumour progression, the role of VEGF is less clear. Jacobsen et al. [28] postulate that lower VEGF-A expression in higher tumour nuclear grade and pathological tumour stage can result due to other proliferative and angiogenic factors overcoming VEGF-A expression. Thus, these other factors may have a key role in disease progression and short survival in patients with metastatic CCRCC. The complexities of multiple different growth factors are not completely understood, and their role and relationship remain important as a subject of future investigation in RCC [29] .
In conclusion, this study demonstrates that tumour VEGF-A expression is a valuable prognostic indicator of low-grade CCRCC and can be used to stratify advanced and metastatic CCRCC patients into low-benefit and high-benefit groups. High VEGF-A expression patients will benefit from anti-angiogenic treatment with VEGF blockers or VEGF receptor blockers. On the other hand, low VEGF-A expression patients will not benefit from this therapy, and they should be treated with alternative medications.
Therefore, we recommend that performing IHC staining for VEGF-A expression would be very useful in the treatment strategy of patients with CCRCC. 
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